- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07392229
Zanubritnib og Anti-MAG-neuropati (MAZINGA)
Zanubrutinib, en andre generasjons BTK-hemmer, ved anti-MAG-antistoff-neuropati: en fase II italiensk multicenter klinisk studie (MAZINGA)
The MAZINGA study is a multicenter, open-label, single-arm Phase IIA clinical trial designed to evaluate the efficacy, safety, and tolerability of zanubrutinib in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) antibody-associated demyelinating polyneuropathy. Anti-MAG neuropathy is a rare immune-mediated disorder frequently associated with IgM monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia, and other indolent B-cell lymphoproliferative disorders.
The primary objective of the study is to determine whether 12 months of treatment with zanubrutinib leads to a clinically meaningful neurological improvement, defined as an improvement of at least one point in at least two validated neurological scales. These include reductions in the Overall Neuropathy Limitations Scale (ONLS), INCAT Disability Score, and INCAT Sensory Sum Score (ISS), along with increases in the Medical Research Council (MRC) sum score and the I-RODS functional score.
Secondary objectives include the evaluation of neurophysiological improvement assessed by nerve conduction studies (ENG/EMG), particularly changes in distal motor latency, terminal latency index, and sensory action potential amplitude at 12, 24, and 48 months. Additional secondary endpoints assess hematological efficacy through overall response rate (complete response, very good partial response, or partial response), event-free survival, time to neurological progression, and overall survival. The safety profile of zanubrutinib will be characterized by the incidence, type, and severity of adverse events, serious adverse events, and events of special interest.
Eligible participants are adults (≥18 years) with a confirmed diagnosis of anti-MAG IgM-associated demyelinating polyneuropathy, evidence of a relevant IgM monoclonal gammopathy, elevated anti-MAG antibody titers, and measurable neurological disability. Both treatment-naïve and relapsed/refractory patients are eligible. Key exclusion criteria include prior treatment with BTK inhibitors, aggressive lymphomas, significant axonal damage, uncontrolled comorbidities, active infections, pregnancy, or conditions that could interfere with study participation or safety evaluation.
The planned sample size is approximately 50 patients recruited from nine Italian centers. Statistical analyses will compare neurological outcomes with historical controls, estimate survival endpoints using Kaplan-Meier methods, and explore associations between clinical outcomes and molecular features. This study aims to provide robust prospective evidence on the role of BTK inhibition in anti-MAG neuropathy and to inform future therapeutic strategies for this rare and disabling condition.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Andrea Visentin, Dr, Medical Doctor
- Telefonnummer: +39 049 821 2298
- E-post: ANDREA.VISENTIN@UNIPD.IT
Studer Kontakt Backup
- Navn: Manuela Taurisano, Pharmacy, PhD
- Telefonnummer: +39 3513590476
- E-post: mtaurisano@clinopshub.com
Studiesteder
-
-
Milan
-
Milan, Milan, Italia, 20162
- Rekruttering
- CTU Ematologia, Grande Ospedale Metropolitano Niguarda
-
Hovedetterforsker:
- Anna Maria Frustaci, MD
-
Ta kontakt med:
- Anna Maria Frustaci, MD, Medical Degree (Hematology)
- Telefonnummer: +390264442668
- E-post: annamaria.frustaci@ospedaleniguarda.it
-
Ta kontakt med:
- Lucia Bacigaluppi
- Telefonnummer: +390264447597
- E-post: lucia.bacigaluppi@ospedaleniguarda.it
-
Milan, Milan, Italia, 20089
- Rekruttering
- Neuroimmunology and neuromuscular disease unit, IRCCS Ospedale Clinico Humanitas di Rozzano, Milano
-
Ta kontakt med:
- Pietro Emiliano Doneddu, MD, Medical Degree (Neurology)
- Telefonnummer: (+39) 0282247761
- E-post: pietro.doneddu@hunimed.eu
-
-
PD
-
Padova, PD, Italia, 35128
- Rekruttering
- UOC Ematologia, Azienda Ospedale Università Padova
-
Hovedetterforsker:
- Andrea Visentin, MD
-
Ta kontakt med:
- Andrea Visentin, MD, Medical Degree (Hematology)
- Telefonnummer: +39 049 821 2298
- E-post: andrea.visentin@aopd.veneto.it
-
-
PV
-
Pavia, PV, Italia, 27100
- Rekruttering
- SC Ematologia 1 - Fondazione IRCCS Policlinico San Matteo
-
Ta kontakt med:
- Martina La Fauci
- Telefonnummer: +39 0382503084
- E-post: cto-oh@smatteo.pv.it
-
Hovedetterforsker:
- Marzia Varettoni, MD
-
-
RM
-
Roma, RM, Italia, 00168
- Rekruttering
- UOSD Leucemia Linfatica Cronica, Fondazione Policlinico Universitario "A. Gemelli", IRCCS
-
Ta kontakt med:
- Florenzia Vuono
- Telefonnummer: +39 0630157833
- E-post: florenzia.vuono@policlinicogemelli.it
-
Hovedetterforsker:
- Luca Laurenti, MD
-
-
TO
-
Torino, TO, Italia, 10126
- Rekruttering
- SC Ematologia U, Ospedale Molinette, Torino (TO)
-
Ta kontakt med:
- Simone Ferrero, MD, Medical Degree (Hematology)
- Telefonnummer: +39 0116334220
- E-post: simone.ferrero@unito.it
-
-
Trieste
-
Trieste, Trieste, Italia, 34129
- Rekruttering
- SC UCO Ematologia, Ospedale Maggiore di Trieste
-
Hovedetterforsker:
- Francesco Zaja, MD
-
Ta kontakt med:
- Francesco Zaja, Prof., Medical Degree (Hematology)
- Telefonnummer: +390403992015
- E-post: francesco.zaja@asugi.sanita.fvg.it
-
Ta kontakt med:
- Maria Chiara Rossetti
- Telefonnummer: + 390403992897
- E-post: mariachiara.rossetti@asugi.sanita.fvg.it
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria (MAIN):
- age ≥18 years;
- diagnosis of anti-MAG antibody polyneuropathy;
- neurophysiological (ENG/EMG) evidence of a demyelinating polyneuropathy with evidence of disproportionately prolonged distal motor latency in one or more nerves -excluding the median nerve if related to carpal tunnel syndrome
- IgM monoclonal protein underlying MGUS (based on the WHO definition of clonal lympho- plasmocytes <10%), Waldenstrom macroglobulinemia (based on the WHO definition of clonal lympho-plasmocytes ≥10%), marginal zone lymphoma, chronic lymphocytic leukemia or low- grade lymphoma not otherwise specified;
- presence of anti MAG antibodies (titer ≥ 7.000 BTU);
- neurophysiological (ENG/EMG) evidence of demyelinating polyneuropathy.
Exclusion Criteria (MAIN):
- Previous treatment with BTK inhibitors
- Aggressive non-Hodgkin lymphoma or IgM multiple myeloma
- Evidence of moderate or severe motor nerve axonal damage, defined when occurring diffuse polyneuropathic denervation or a recruitment pattern lower than intermediate in ≥50% of muscles examined, and/or INCAT at lower limbs ≥4.
- ECOG >3
- Use of strong CYP3A inducers within 14 days prior to the first dose of zanubrutinib
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Treatment arm
Zanubrutinib |
ZANUBRUTINIB ORAL CAPSULES or Brukinsa Oral Capsule |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Andelen pasienter med nevrologisk forbedring definert som forbedring på minst 1 poeng etter 12 måneders zanubrutinib-behandling.
Tidsramme: 5 år
|
5 år
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- MAZ-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .